Prognostic Value of Serum Levels of Tumor Necrosis Factor-Alpha in Patients with Heart Failure

Alejandro J. Jordán, Ángel Esteban, Miguel García, José V. Monmeneu, Dolores Espinosa, Fernando Reyes, Juan Luján, Vicente Climent, Francisco Marín, and Fernando García de Burgos

Introduction and objective. Tumor necrosis factor-alpha is an inflammatory cytokine which rises in heart failure and has prognostic value in severe cases. Its value is less established in moderate cases. Our aim was to determine its prognostic value in cases from a community hospital.

Patients. We studied 50 patients, average age 59.5 ± 12.3 years, with dilated cardiomyopathy (72% non-ischemic) and moderate heart failure (59% functional class II).

Methods. Patients were evaluated with an echocardiogram and cardiopulmonary treadmill stress test (Naughton), muscular strength measurements (hand dynamometer), blood tumor necrosis factor levels, and an average follow-up of 17.5 ± 9 months (range, 1-29 months). All causes of mortality, cardiac transplantation, and readmissions for heart failure were recorded.

Results. Twenty-three patients experienced events. These patients were older (63 ± 12.7 vs 55.7 ± 11.4 years; \( p = 0.042 \)), had a lower peak VO\(_2\) (13.7 ± 3.9 vs 16 ± 3.3 ml/kg/min; \( p = 0.035 \)), and higher peak VE/VCO\(_2\) and factor levels (41.9 ± 10.6 vs 33.2 ± 5.7; \( p = 0.001 \)) and 4.3 (3.1-7.9) vs 3.3 (2.4-4.3) pg/ml; \( p = 0.021 \), respectively). In the Cox model, the only variable with independent prognostic value was peak VE/VCO\(_2\) (3.1-7.9) vs 3.3 (2.4-4.3) pg/ml; \( p = 0.021 \), respectively). The best cutoff point was 34.5 (sensitivity, 86.4%; specificity, 58.3%; \( p = 0.0007 \)). The cytokine had no independent prognostic value.

Conclusions. Our patients with events were older, had a lower peak VO\(_2\), and higher peak VE/VCO\(_2\) and serum tumor necrosis factor levels. However, only peak VE/VCO\(_2\) had independent prognostic value.

Key words: Heart failure. Cytokines. Prognosis.

Full English text available at: www.revespcardiol.org

INTRODUCTION

Tumor necrosis factor alpha (TNF-\(\alpha\)) is an inflammatory cytokine that is elevated in patients with congestive heart failure (CHF),\(^1\) and that has been found to be associated with the genesis of cardiac cachexia.\(^2\)
ABBREVIATIONS

TNF-α: tumor necrosis factor alpha.
CHF: congestive heart failure.
pVO₂: peak oxygen consumption.
pVE/VCO₂: peak carbon dioxide ventilation equivalent.
BMI: body mass index.

TNF-α is associated with, on one hand, musculoskeletal atrophy, and on the other hand it produces a negative inotropic effect. Nevertheless, it does not appear to be related to neurohumoral activation in CHF. In a study by Rauchhaus et al., performed on patients with CHF caused by systolic dysfunction in (predominantly) functional class III and IV, it was reported that the plasma values of TNF-α receptor 1 had an independent prognostic value, adjusted for the ejection fraction (EF) and peak oxygen consumption (pVO₂). Similarly, in the placebo group of the VEST study, which included patients with CHF caused by systolic dysfunction in functional classes III and IV, TNF-α plasma values and the TNF-α circulating receptors 1 and 2 were independent predictors of death, after adjusting for EF and functional class. Nevertheless, in patients in the SOLVD study (NYHA functional class I to II), the plasma values of TNF-α had a tendency to be independent predictors of survival (P<0.07).

The goals of our study were:

1. To determine the relationship between TNF-α blood levels and: a) the severity of CHF as evaluated by pVO₂; b) ventricular function as evaluated by the EF; c) the patients’ nutritional level as evaluated by body mass index (BMI), and d) muscular strength as evaluated by a hand-held dynamometer.

2. To find out the prognostic value of serum TNF-α values in patients with CHF and controlled left ventricular systolic dysfunction in secondary hospitals (Hospitales de Elche and Alicante), corrected for variables of known prognostic value (EF, pVO₂, peak carbon dioxide ventilation equivalent [VE/VCO₂], BMI).

Our hypothesis was, primarily, that TNF-α has a negative correlation with pVO₂, contractility (measured as EF), nutrition level (measured as BMI), and muscle strength. Secondly, we theorized that in patients with CHF, TNF-α has an independent prognostic value.

The Hospital de Elche treats a population of approximately 250,000 inhabitants and has noninvasive cardiology techniques available. The Hospital de Alicante treats a slightly smaller population (approximately 230,000) and offers invasive techniques (hemodynamic and electrophysiological). Neither center is a referral center for cardiac transplants.

PATIENTS AND METHODS

Inclusion criteria

Patients with clinical CHF and left ventricular systolic dysfunction (EF<0.50), in other words, with dilated cardiomyopathy of any etiology, were included. At the time of the study, the patients were stable, without pleural effusion, ascitis, or edema. Patients also had to be free of anti-inflammatory drugs and steroids during the previous 2 weeks.

Exclusion criteria

– Significant aortic stenosis. Hyperdynamic cardiac insufficiency.
– Orthopedic or rheumatic problems that prevented ambulation
– Documented chronic air flow obstruction. (In questionable cases, spirometry was performed.)
– Occurrence of an acute myocardial infarction during the previous 3 months. Clinical occurrence of chest pain (stress or unstable).
– In the presence of ischemic cardiopathy, existence of a complete left bundle branch block.
– Signs of acute infection, diagnosis of neoplasia, thyroid disease, chronic liver disease, neuromuscular disease, advanced renal insufficiency, and collagenosis.

Patients were selected consecutively from the database of the hospital’s Servicio de Documentación Clínica (clinical documentation service) (patients diagnosed upon hospital discharge with heart failure and dilated cardiomyopathy of any etiology). After reviewing the clinical history, we selected the patients who met the inclusion criteria and did not meet any of the exclusion criteria. We included all patients who met all required criteria after testing was completed.

We used the following methods:
– M-mode, 2D, and Doppler echocardiogram (Toshiba SSH-140; 2.5 MHz transducer). We recorded: a) the EF by the Teicholz method or ellipsoid single-plane algorithm (4-chamber apical) in cases of ventricular asynergy, and b) the left ventricular diameter in diastole (LVDD). The values are the average of 3 heartbeats.
– Cardiopulmonary stress test as usually performed (Marquette MAX 1 treadmill), following the Naughton protocol. The test was stopped at the point of exhaustion, and required reaching a respiratory exchange ratio ≥1. We measured the pVO₂ anaerobic thres-
hold with the V slope method, the exertion time, and the peak VE/VCO\textsubscript{2} \cite{19} (CPX Express. Medgraphics. Cardiorespiratory Diagnostic Systems), and calculated the product of cardiac frequency multiplied by arterial pressure.

- Determination of TNF-\(\alpha\) plasma values using the ELISA technique (Quantikine, R&D Systems).
- Measurement of muscle strength (average of 3 measurements) with hand-held dynamometer. Measurement was performed on the dominant hand, with the patient standing and the forearm extended, contracting the hand progressively until reaching maximum strength.

**Statistical analysis**

The normal distribution continuous variables were described as mean±standard deviation (SD), and those that did not follow normal distribution were described as median (25\textsuperscript{th} to 75\textsuperscript{th} percentiles).

The comparisons of the groups (patients with and without episodes) for continuous variables were performed with the Student \(t\) test for independent samples (normal values) or the Mann-Whitney \(U\) test (variables without normal distribution). The comparison of discrete variables was done via the \(\chi^2\) test or the Fisher test (with expected frequencies <5).

The relationship between TNF-\(\alpha\) and the remaining continuous variables was studied using the Pearson correlation test; we used the Spearman rank correlation test when any of the variables did not follow a normal distribution. During followup of the cardiovascular events (which was performed by reviewing the clinical history and by telephone interview) we documented death due to any cause, readmission due to CHF, and cardiac transplant. We performed stepwise Cox proportional hazard model analysis, considering the endpoint to be the presence of any event and introducing as explanatory variables age, sex, BMI, cause of the CHF (ischemic or non-ischemic dilated cardiomyopathy), cardiac rhythm (sinus or non-sinus), EF, p\(\text{VO}_2\), p\(\text{VE}/\text{VCO}_2\), TNF-\(\alpha\), and muscle strength. We analyzed survival that was event-free using the Kaplan-Meier method. We obtained Receiver Operating Characteristics (ROC) curves from the variables with independent prognostic value and from TNF-\(\alpha\) values in order to obtain the best cut points for these variables which allowed us to separate the groups of patients with different prognoses. The comparison of survival rates obtained from the various groups was done by the log-rank test. We chose as the cut-off point the value that corresponded to the highest product of the sensitivity multiplied by specificity, always when the log-rank test was significant. The statistical analysis was performed with the SPSS 10.0 statistical package.

**RESULTS**

Fifty patients were included in the study. Their baseline clinical characteristics are shown in Table 1. The patients were categorized into New York Heart Association (NYHA) class I-III (only 1 patient was class IV), with most patients categorized as class II (59\%). There were no cachexic patients: 48 of the 50 patients had a BMI>20 kg/m\textsuperscript{2}. Twenty-six percent of patients had atrial fibrillation. In our series, only 28% of patients had ischemic dilated cardiomyopathy. In our hospitals coronary angiography is not routinely performed on all patients with systolic dysfunction and CHF, unless clinical, electrocardiographic, or echocardiographic data (ventricular asynery) point to suspected ischemic cardiopathy. Therefore, it is possible that the prevalence of ischemic dilated cardiomyopathy may be somewhat high in our study. The patients were treated with digitalis (64\%), diuretics (85\%), spironolactone (48\%), angiotensin-converting enzyme inhibitors I (64\%), angiotensin II receptor inhibitors (30\%), nitrates (15\%), and beta-blockers (6\%).

The functional capacity (p\(\text{VO}_2\)) had a negative correlation with the TNF-\(\alpha\) (variable that was not adjus-

**TABLE 1. Clinical characteristics**

<table>
<thead>
<tr>
<th>N</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>59.5±12.3</td>
</tr>
<tr>
<td>Sex, M, n (%)</td>
<td>36 (72%)</td>
</tr>
<tr>
<td>BMI, kg/m\textsuperscript{2}</td>
<td>28.2±4.9</td>
</tr>
<tr>
<td>Cause, n (%)</td>
<td>ISQ DCM 14 (28)</td>
</tr>
<tr>
<td>NYHA, n (%)</td>
<td>I: 6 (12.2)</td>
</tr>
<tr>
<td>Rhythm, n (%)</td>
<td>SR: 34 (69.4)</td>
</tr>
<tr>
<td>EF</td>
<td>0.33±0.08</td>
</tr>
<tr>
<td>LVDD, mm</td>
<td>64.3±8.4</td>
</tr>
<tr>
<td>p(\text{VO}_2), mL/kg/min</td>
<td>14.9±3.8</td>
</tr>
<tr>
<td>Exercise time, min</td>
<td>8.8±3.6</td>
</tr>
<tr>
<td>DP</td>
<td>21 013±6090</td>
</tr>
<tr>
<td>Strength, kg</td>
<td>46.9±37.1</td>
</tr>
<tr>
<td>TNF-(\alpha), pg/mL</td>
<td>3.9 (2.9-5.3)</td>
</tr>
<tr>
<td>p(\text{VE}/\text{VCO}_2)</td>
<td>37.7±9.5</td>
</tr>
</tbody>
</table>

Data about rhythm was known in 49 patients. There was no data on the NYHA class of 1 patient (but their p\(\text{VO}_2\) was available). ALC indicates alcoholic; LVDD, left ventricle diastolic diameter; DP, double product; AF, atrial fibrillation; EF, ejection fraction; AHT, arterial hypertension; ID, idiopathic; MR, mitral regurgitation; BMI, body mass index; ISQ, ischemic; DCM, dilated cardiomyopathy; SR, sinus rhythm; TNF-\(\alpha\), tumor necrosis factor alpha; M, men; p\(\text{VE}/\text{VCO}_2\), peak carbon dioxide ventilation equivalent at peak exercise; p\(\text{VO}_2\), peak oxygen consumption.
Jordán AJ, et al. Prognostic Values of Serum Levels of Tumor Necrosis Factor-Alpha in Patients with Heart Failure

71

Rev Esp Cardiol 2003;56(2):160-7

Fig. 1. Spearman correlation between TNF-α and pVO₂ values (the TNF-α does not have normal distribution). pVO₂ indicates peak oxygen consumption; TNF-α, tumor necrosis factor alpha.

ted to normal; Spearman r=–0.29; P=.043; Figure 1).

The rest of the variables we studied did not have a significant correlation with the TNF-α (EF: r=–0.15; P=.30. BMI: r=–0.02; P=.90. Strength: r=–0.19; P=.20).

The patients were followed for 17.5 months±9 months (range 1 to 29). We were unable to obtain complete information from 2 patients: 1 whose whereabouts were unknown and the other whose survival was only known anecdotally, but there is no data on the other 2 events during the study, and they were excluded from the analysis of the group of patient who survived without events (analysis of 48 patients total). Ten patients died (20.4%), 19 were readmitted due to CHF (39.6%), and 2 (4.2%) underwent cardiac transplant. Overall, 23 patients (47.9%) had some type of event.

The patients who had events did not differ from those who did not by sex, BMI, left ventricle diastolic diameter, EF, or muscle strength (Table 2). The patients who had events were found to be in sinus rhythm less frequently than those who did not (59.1% vs 84%; P=.056), and showed a tendency to have a higher occurrence of ischemic dilated cardiomyopathy than those who had no cardiovascular events (39.1% vs 16%; P=.071). The group with cardiovascular events were older (63 years versus 56 years; P=.042) and had a lower pVO₂ (13.7 mL/kg/min vs 16 mL/kg/min; P=.035) and a higher pVE/VCO₂ (41.9 vs 33.2; P=.001), and a higher TNF-α (4.3 pg/mL vs 3.3 pg/mL; P=.021).

A stepwise Cox proportional hazards model analysis as performed, introducing the 10 preselected clinical and analytical variables. The only variable that showed an independent predictive value for a cardiovascular episode was the pVE/VCO₂ (χ²=34.68; P<.001; hazard ratio [RR], 1.13 [1.07–1.19]). The TNF-α values did not have an independent prognostic value (P=.087).

<table>
<thead>
<tr>
<th>Table 2. Comparison of patients according to the presence of events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Events</strong></td>
</tr>
<tr>
<td>N</td>
</tr>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>Sex, M, n (%)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
</tr>
<tr>
<td>Cause, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>NYHA, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Rhythm, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>LVDD, mm</td>
</tr>
<tr>
<td>EF</td>
</tr>
<tr>
<td>DP</td>
</tr>
<tr>
<td>Strength, kg</td>
</tr>
<tr>
<td>TNF-α, pg/mL</td>
</tr>
<tr>
<td>Effort time, min</td>
</tr>
<tr>
<td>pVO₂, mL/kg/min</td>
</tr>
<tr>
<td>pVE/VCO₂</td>
</tr>
</tbody>
</table>

Followup of 2 patients was not possible. Data on rhythm was unknown in 1 patient. There was no data on the NYHA class of 1 patient (but the VO₂ was known). LVDD indicates left ventricle diastolic diameter; DP, double product; BMI, body mass index; ISQ, ischemic; DCM, dilated cardiomyopathy; SR, sinus rhythm; TNF-α, tumor necrosis factor alpha; M, men; pVE/VCO₂, pVE/VCO₂, peak carbon dioxide ventilation equivalent at peak exercise; pVO₂, peak oxygen consumption.
The probability of survival free of events at 7 months was 85% (80% to 90%), at 15 months was 68% (61% to 75%), and at 26 months was 28% (25% to 31%), with all the events having taken place (Figure 2).

Using the ROC curves, we obtained the best pVE/VCO$_2$ value that significantly separated 2 groups of patients with different prognoses. This value was 34.5 (sensitivity, 86.4%; specificity, 58.3%; RR, 2.53 [1.37 to 4.70]; P=.0007; Figure 3). Although it did not have an independent prognostic value, we used the same analysis for TNF-α blood values, and we obtained the number 2.92 pg/mL (sensitivity, 87%; specificity, 40%; RR, 1.85 [1.003 to 3.415]; P=.035; Figure 4).

**DISCUSSION**

We studied a group of patients who basically had idiopathic and ischemic dilated cardiomyopathy with moderate CHF (predominantly NYHA functional class II) without cachexia. The serum TNF-α values were found to be similar to those reported in the analyses of serum in the SOLVD study. Milani et al$^{21}$ and Testa et al$^{22}$ also reported similar values in their patients. There are studies that report no elevation of TNF-α in patients with slight to moderate CHF.$^{18,23}$

Muscle changes have been described in patients with CHF. Massie et al$^{24}$ found a lower muscle fatigue index in the quadriceps (greater decrease in strength after 15 successive contractions) in patients compared with controls. In addition, the patients had less type I and more type II a and b fibers, and less succinate dehydrogenase enzyme activity. In short, the activity of this enzyme had a positive correlation with the pVO$_2$. Volterrani et al$^{25}$ found a clear positive correlation between quadriceps strength and pVO$_2$. In our study, however, we did not find a relationship between muscle strength and functional capacity among our patients (pVO$_2$; Pearson r, 0.23; P=.112).

We have found that a significant negative correlation exists between TNF-α values and pVO$_2$ (r, −0.29; P=.043). Other studies have found that as functional class worsens, the TNF-α values increase; our results are in accordance with previous data. We did not
observe, however, a relationship between TNF-α and BMI or with muscle strength, perhaps because patients with moderate CHF were included. However, in experimental studies in rats with CHF, it has been shown that when TNF-α values are lowered with irbesartan, an angiotensin II AT1 receptor antagonist, the animals have reduced atrophy of the skeletal muscle. It is possible that patients categorized as functional class IV may confirm this relationship. In fact, in a study by the London National Heart and Lung Institute,27 patients with CHF and slightly elevated TNF-α values (0.98 to 4.90 pg/mL), similar values to the patients in our series, also did not have a decrease in muscle strength of the quadriceps. This only occurred in those patients with elevated cytokine values (9.8-32 pg/mL), who were also the group of patients who showed greater functional deterioration (pVO2, 13.1 mL/kg/min±4.1 mL/kg/min; in our study the pVO2 was 14.9 mL/kg/min±3.8 mL/kg/min).

We know that patients with CHF have a volume per minute ventilation for each PCO2 greater than the normal individuals. Therefore, in order to study ventilation in CHF, the VE/VCO2 at peak of exercise is used, or the gradient of the ratio of these parameters during exercise is used.19 Many reasons have been put forth to explain this hyperventilation, eg, an increase in the physiological dead space due to pulmonary hypopfusion, dependent receptor mechanisms (metabolic receptors?) in skeletal muscle,19 and decrease in inspiratory muscle strength.28

Our patients had a somewhat high mortality rate (20%), with a 28% probability of being free of episodes at the end of the followup period. The only factor with independent prognostic value was the pVE/VCO2, more than the pVO2 and the TNF-α. Although the prognostic value of pVO2 is generally accepted,13,14 some studies have reported that pVE/VCO2 has an independent prognostic value. Similarly, in a series of patients with CHF, serious systolic dysfunction, and good exercise capacity (pVO2>18 mL/kg/min),16 pVE/VCO2 (and not VO2) influenced the mortality rate. Patients with an elevated pVE/VCO2 (>34, the number obtained after a study of the normal population) had an elevated central and peripheral chemosensitivity and a decreased baroreflexive sensitivity; this value differentiated 2 groups of patients with different survival rates and is very similar to the higher prognostic cut-off value that we obtained (>34.5).

Rauhhaus et al11 published a study of patients with CHF and systolic dysfunction, 29% of whom were cachexic. In that series, the type 1 circulating receptors of TNF-α had an independent prognostic value, along with pVO2 and EF values. Similarly, in the placebo group of the VEST study (patients with CHF and NYHA functional class III and IV),12 both the circulating values of TNF-α and the type 1 and 2 circulating receptor values of the cytokine influenced the survival rate independently, along with the NYHA functional class and the EF, although the type 2 circulating receptors had the greatest predictive value. Nevertheless, in a recent study from the Hospital Clinic de Barcelona of patients with CHF and classified as NYHA class III-IV who had systolic dysfunction,29 only the angiotensin II values, along with the cardiac index and pulmonary capillary pressure, had an independent predictive value for death or cardiac transplant. In that study, the authors analyzed, among other variables, the TNF-α and interleukin8 values. In our study, only the pVE/VCO2 ventilation index could independently predict survival.

The differences between the aforementioned studies and our study should be pointed out. In the Rauhhaus study, 57% of the patients were in NYHA functional classes III-IV. In the VEST study, all the patients were in the same functional classes, as were the patients in the study from the University of Berlin,11 the cytokines had prognostic value in spite the fact that 20% of patients had this EF. In addition, the EF in our study overlapped in the groups with and without events. The overall mortality rate of the 4 series is different: a rate of 41% at an average follow-up of one year (maximum followup period, 6 years) in the Rauhhaus study, 17% at 1-year mean followup (maximum followup period of 19 months) in the VEST study, and 16% (47% death or cardiac transplant) per year in the study from the Hospital Clinic de Barcelona,29 vs a rate of 20% at a mean 18-month followup (maximum followup period 29 months) in our series. One factor that may have influenced the patient course is treatment with beta-blockers: these were prescribed in 12% of patients in the Rauhhaus series, 25% of patients in the Barcelona study, and 6% of our patients (this was not a factor in the VEST study). The scant use of these drugs in our series may explain the relatively high mortality rate. Another difference between the studies that may explain differences in the prognostic value of TNF-α is the final followup point: death due to any cause in the Rauhhaus and VEST studies, death due to any cause or cardiac transplant in Hospital Clinic de Barcelona study, and death due to any cause, cardiac transplant, or readmission due to CHF in our study.

Nevertheless, in the study by Torre-Amione,10 which was performed on patients from the SOLVD...
study in NYHA functional classes I to III, the blood values of TNF-α alone tended to be of independent prognostic value (P=.07), which is a result that is compatible with ours from patients in similar functional classes (90% in NYHA functional classes II-III; 86% in our series).

**Study limitations**

Our study was performed in a small sample size, which could have had an effect on the results of the multivariate analysis. In our series, 26% of patients had an EF between 0.4 and 0.5; this may have influenced the prognosis, making it more favorable, although in the other series mentioned such as the Rauchhaus series, with a similar rate (20%), the mortality rate was double. The small number of patients treated with beta-blockers could have influenced the prognosis, making it more unfavorable. In our study we only determined the values of circulating TNF-α, and did not analyze the values of the TNF-α circulating receptors. Nevertheless, although there are studies in which only the circulating receptor values have independent prognostic value, other studies TNF-α also has prognostic value, although it is less than that of circulating receptors. Since this is a non-invasive clinical study, we do not know the myocardial TNF-α values. It has been reported that although almost all patients with elevated myocardial TNF-α also have elevated circulating TNF-α, only approximately 50% of patients with increased circulating TNF-α have increased myocardial TNF-α; nevertheless, we know of no study that has analyzed whether myocardial TNF-α has a greater prognostic value than its circulating values. Our followup endpoint was a combination of episodes, not only death, so that our results are not comparable to other series in the literature.

**CONCLUSIONS**

1. In patients with moderate CHF due to left systolic ventricular dysfunction without cachexia, we did not find a relationship between serum TNF-α values and EF, the nutrition level, or muscle strength.

2. Circulating TNF-α has a negative correlation with functional capacity, measured as pVO₂.

3. The group of patients with the cardiac events are older, have a smaller pVO₂, have a higher pVE/VCO₂, with independent prognostic value, and have higher TNF-α values, although they do not add prognostic value.

**REFERENCES**


